392
Participants
Start Date
February 4, 2021
Primary Completion Date
March 18, 2022
Study Completion Date
February 1, 2023
TQB2450 Injection
TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
Anlotinib hydrochloride
Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Oxaliplatin injection
Oxaliplatin injection 130 mg/m2 administered IV on Day 1 of each week in 3-week cycles;
Capecitabine tablets
Capecitabine tablets total dose 2000 mg/m2, oral twice a day from Day 1-14 of each 3- week cycles;
Gemcitabine hydrochloride injection
Gemcitabine hydrochloride injection administered 1000 mg/m2 IV on Day 1 and Day 8 of each week in 3-week cycles.
NOT_YET_RECRUITING
Beijing Chao-Yang Hospital,Capital Medical University, Beijing
NOT_YET_RECRUITING
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
NOT_YET_RECRUITING
Peking University People's Hospital, Beijing
NOT_YET_RECRUITING
Beijing Youan Hospital,Captical Medical University, Beijing
RECRUITING
Beijing Cancer Hospital, Beijing
NOT_YET_RECRUITING
Beijing Tsinghua Changgung Hospital, Beijing
NOT_YET_RECRUITING
The First Bethune Hospital of Jilin University, Changchun
NOT_YET_RECRUITING
Harbin Medical University Affiliated Tumor Hospital, Harbin
NOT_YET_RECRUITING
The First Peoples Hospital of Changzhou, Changzhou
NOT_YET_RECRUITING
Anhui Provincal Hospital, Hefei
NOT_YET_RECRUITING
Fujian Medical University Union Hospital, Fuzhou
NOT_YET_RECRUITING
Hunan Provincial People's Hospital, Changsha
NOT_YET_RECRUITING
Tongji Medical College of HUST, Wuhan
NOT_YET_RECRUITING
Henan Tumor Hospital, Zhengzhou
NOT_YET_RECRUITING
Affiliated Hospital of Hebei University, Baoding
NOT_YET_RECRUITING
Cangzhou Central Hospital, Cangzhou
NOT_YET_RECRUITING
Affiliated Hospital of Chengde Medical University, Chengde
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY